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Abstract 
Purpose: To evaluate diagnostic performances of CESM for breast diseases with comparison to breast MRI in China.
Materials and methods: Sixty-eight patients with 77 breast lesions underwent MR and CESM. Two radiologists 
interpreted either MRI or CESM images, separately and independently. BI-RADS 1–3 and BI-RADS 4–5 were classi-
fied into the suspicious benign and suspicious malignant groups. Diagnostic accuracy parameters were calculated. 
Receiver operating characteristic (ROC) curves were constructed for the two modalities. The agreement and correla-
tion between maximum lesion diameter based on CESM and MRI, or CESM and pathology were analyzed.
Results: Diagnostic accuracy parameters for CESM were sensitivity 95.8 %, specificity 65.5 %, PPV 82.1 %, NPV 90.5 % 
and accuracy 84.4 %. The diagnostic accuracy parameters for breast MRI were sensitivity 93.8 %, specificity 82.8 %, PPV 
88.2 %, NPV 92.3 %and accuracy 89.6 %. Area under the curve (AUC) of ROC was 0.96 for breast MRI and 0.88 for CESM. 
The Bland–Altman plots showed a mean difference of 0.7 mm with 95 % limits of agreement of 11.4 mm in tumor 
diameter measured using CESM and breast MRI. The differences of size measurement between CESM and breast MRI 
were significant, whereas no difference was observed between CESM and pathology as well as between breast MRI 
and pathology. The better correlation with pathological results was found in CESM than breast MRI.
Conclusion: Our study demonstrates that CESM possesses better diagnostic performances than breast MRI in terms 
of diagnostic sensitivity and lesion size assessment. And CESM is a good alternative method of screening breast can-
cer in high-risk people.
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Background
Early detection and diagnosis are essential for the prog-
nosis and treatment of breast cancer. The most com-
monly used methods include digital mammography 
(DM), ultrasound (US) and magnetic resonance imaging 
(MRI).
DM has a low diagnostic sensitivity and specificity in 
women with dense breasts due to its masking effects 
(Pisano et  al. 2005). The US is usually considered as a 
supplemental screening method for women with dense 
breasts to increase the detection of breast cancer. How-
ever, hand-held US screening by the radiologist has a 
high false-positive rate, which may not be a preferable 
method for breast surgeons (Berg et al. 2008).
At present, MRI is considered the best imaging inves-
tigation for the detection and diagnosis of breast cancer 
(Schell et al. 2009; Pickles et al. 2016; O’Flynn et al. 2016; 
Iacconi et al. 2015). Breast MRI is cost-effective in screen-
ing high-risk women. However, due to high cost and time 
consuming, preoperative breast MRI can’t be widely 
available. There may be a high number of false-positive 
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findings in breast MRI which may cause spiritual anxiety 
and unnecessary treatment.
Contrast enhanced spectral mammography (CESM) is 
a novel breast imaging technique that has been investi-
gated to display contrast up-take in breast lesions (Diek-
mann et al. 2005; Diekmann et al. 2011). CESM improves 
the sensitivity and specificity for breast cancer detection, 
as it provides higher foci to breast gland contrast and 
better lesion delineation than DM (Dromain et al. 2011). 
Preliminary results suggest that, similar to breast MRI, 
CESM had a good practice for evaluating lesion extent, 
lesion size and detecting more multifocal lesions. How-
ever, so far there are only a few studies with regard to 
CESM examinations with comparison to breast MRI.
The purpose of our study was to compare bilateral CESM 
and breast MRI with regard to the diagnosis and size esti-
mation of histologically proven breast diseases using post-
operative histology findings as the gold standard. CESM 
will be considered as a competitive modality if the dif-
ference of diagnosis performance is <10  % compared to 
breast MRI.
Patients
Our institutional review board approved this prospective 
study. Written informed consent form was obtained from 
each patient. The participants should be females present-
ing for breast diagnostic imaging, either with clinical or 
previous suspicious imaging findings.
Inclusion criteria
The participant should be a female over the age of 18 years 
without the history of mammary gland excision. The par-
ticipant shouldn’t be pregnant confirmed by negative urine 
pregnancy test. The participant presents with suspicious 
breast clinical symptoms and/or previous breast findings 
classified BI-RADS  ≥  3 on mammography and/or ultra-
sound. The participant is willing to have all imaging pro-
cedures completed (MRI, CESM) within a 3-week interval.
Exclusion criteria
The breasts of the participant are too large to be ade-
quately demonstrated. The contraindications for contrast 
agents are applied in this study. The subject is undergoing 
radiotherapy or chemotherapy. The participant has acute 
medical condition requiring urgent care. Any conditions 
judged by the Investigator would interfere with the evalu-
ation of the results or cause a potential hazard to the par-
ticipant’s health.
CESM technique and protocol
The CESM equipment  was a commercial model pro-
vided by GE Healthcare (Senographe DS and Senographe 
Essential mammography systems, Buc, Cedex, France). 
An intravenous catheter was inserted in the forearm 
prior to the examination.
An 18-gauge catheter was placed into an antecubital 
vein prior to the examination. A nonionic contrast mate-
rial (Omnipaque, 350  mgI/mL; GE Healthcare, Dublin, 
Ireland) at a 1.5  mL/kg, to a maximum of 90  mL was 
injected at a flow rate of 3.0 mL/s. Consecutive mammo-
gram was performed with craniocaudal (CC) and medi-
olateral oblique (MLO) views of the bilateral breasts at 
2  min after completion of contrast agent injection. All 
four views completed within 5 min. A pair of low-energy 
(LE) and high-energy (HE) images is acquired within 1 s 
under normal mammographic compression in each pro-
jection (Fig. 1).
MR examination
All MR examinations were performed on a 1.5-T MR sys-
tem (Signa HDx, GE Medical System, Milwaukee, WI, 
USA) in prone position using a four-channel breast coil.
Diffusion-weighted imaging (b  =  800  sec/mm2) and 
dynamic T1w Vibrant 3D gradient echo sequences (rep-
etition time 5.2 ms, echo time 2.1 ms, flip angle 15°, field 
of view 320–360 mm, 512 × 512 matrix, slice thickness 
2.0  mm, no intersection gap). After the unenhanced 
fat-saturated T1WI, five contrast enhanced image sets 
with a gap of 1.7-s were acquired with a 15-s delay after 
starting the contrast injection, resulting in an individual 
duration for one acquisition of 46–75. Contrast agents 
(Magnevist®, Bayer-Healthcare, Germany) with a dose 
of 0.1 mmol/kg body weight were injected using an auto-
mated syringe at a rate of 2 ml/s as a single intravenous 
bolus followed by a 20 ml saline flush.
Image reading method
Our study was a blinded on truth and non-randomized 
research. The MRI images were anonymized by a study 
coordinator prior to study readings. The CESM images 
were anonymized at the time of acquisition with the sub-
jects’ unique study number. Two radiologists were asked 
to read images. They were blinded to the patients’ clinical 
data and had no experience with CESM. They interpreted 
either MRI or CESM images, separately and indepen-
dently (Fig.  2). MG or ultrasound of the case was not 
available to the readers. CESM interpretation included 
both low energy and subtracted (iodine) images. How-
ever, they had experience with breast sonography, digital 
mammography (DM) and breast MRI. The radiologists 
recorded separately for MRI and CESM the most suspi-
cious finding for each breast of the subject. The two read-
ers involved in the study exchanged their work weekly. 
Patient management decisions may involve a consensus 
meeting: if the CESM reading shows additional informa-
tion versus MRI, the Study Coordinator will organize a 
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consensus meeting between the radiologist in charge of 
the patient care and the CESM readers. The consensus 
meeting was organized at the latest 2 weeks after imag-
ing. A consensus decision will be taken on how to use 
the additional information from CESM on patient man-
agement. As such, the radiologist in charge of the patient 
care may go to existing MRI or MG images or possibly 
MG special views or suggest a new ultrasound examina-
tion to refine the diagnosis, as per usual clinical practice. 
CESM images were reviewed using IDI® or SenoAdvan-
tage® workstation with CESM review softwares.
Truth establishment
Truth was derived from tissue sampling and histopathol-
ogy reports for cases with positive assessments on MRI 
and/or CESM. Tissue sampling should be completed in 
maximum 4  weeks after the last study imaging proce-
dure. Cases with negative assessments (BI-RADS ≤ 2) on 
both MRI and CESM were considered as true negatives 
and needn’t require histopathology.
Statistical analysis
For statistical analysis, BI-RADS 1–3 and BI-RADS 4–5 
were classified into the suspicious benign and suspicious 
malignant groups, respectively.
The rates of true positive, true negative, false positive 
and false negative for malignancy were counted. The 
diagnostic sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV) and accuracy 
were calculated.
The differences were tested for statistical significance 
using McNemar’s test for paired proportions. Receiver 
operating characteristic (ROC) curves were constructed 
for the two imaging modalities and the areas under 
the curve (AUC) with corresponding 95  % CI were 
calculated.
Agreement and correlation analysis between maxi-
mum lesion diameter based on CESM and MRI, or 
CESM and surgical specimen was demonstrated by using 
Fig. 1 Schematic overview of procedures in CESM. The low-energy and recombined images on CC and MLO in a 45-year-old volunteer are shown 
according to the order of projection views illustrated in the top of the figure. CC craniocaudal, MLO mediolateral oblique
Fig. 2 Imaging reading procedures
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Bland–Altman plots and Spearman analysis. The differ-
ence of maximum lesion diameter between two groups 
was compared using paired t test (SPSS, version 17, IBM, 
Armonk, NY, USA). P  ≤  0.05 were considered statisti-
cally significant.
Results
A total of 103 patients were initially enrolled in this study. 
Three patients refused contrast agent administration for 
CESM. Fifteen patients refused surgical therapy. Sixteen 
patients had no masses found both on CESM and MRI.
Sixty eight patients with 77 pathologically proven 
lesions were eventually enrolled in this study. Two 
patients each had three lesions, two had two lesions and 
one had four lesions. Thirty six patients were postmeno-
pausal and 32 premenopausal. The patients had a mean 
age of 52.9  years ranging from 31 to 82 (SD  =  10.7). 
CESM and MRI were available for all patients.
Of 77 lesions, 48 lesions were pathologically diagnosed 
as cancer and 29 as benign disease. The most common 
pathological type of breast cancer is invasive ductal car-
cinoma (IDC) (Fig. 3) accounting for 46.8 % (36/77) of all 
lesions. A detailed overview of pathological diagnosis is 
presented in Table 1. Diagnostic accuracy parameters for 
CESM were sensitivity 95.8 % (46/48), specificity 65.5 % 
(19/29), PPV 82.1  % (46/56), NPV 90.5  % (19/21) and 
accuracy 84.4 % (65/77). The diagnostic accuracy param-
eters for MRI were sensitivity 93.8 % (45/48), specificity 
82.8 % (24/29), PPV 88.2 % (42/51), NPV 92.3 % (24/26) 
and accuracy 89.6 % (69/77). CESM detected three can-
cers that were misdiagnosed as benign lesions by MRI 
including one intra-cystic papillary carcinoma and two 
DCIS (Fig.  4). Two inflammatory granulomas (Fig.  5) 
were diagnosed as breast cancer by both CESM and MRI. 
Three fibroadenomas were not shown on recombined 
images whereas clearly shown on low-energy images by 
using CESM.
ROC analysis
Area under the curve (AUC) of ROC was 0.96 for MRI 
and 0.88 for CESM, with a P value for the difference of 
0.03 (Fig. 6).
Lesion size assessment
The Bland–Altman plots showed a mean difference of 
0.7  mm with 95  % limits of agreement of 11.4  mm in 
tumor diameter measured using CESM and breast MRI 
(Fig.  6). A mean difference of 0.2  mm was observed 
between tumor diameters assessed using CESM and his-
topathology, but with smaller 95 % limits of agreement of 
8.2 mm (Fig. 7).
The differences of size measurement between CESM 
and MRI were significant (P  <  0.01), whereas no differ-
ence was observed between CESM and pathology as well 
as between MRI and pathology (P > 0.05). The better cor-
relation with pathology was found for CESM than MRI 
(ρ = 0.975 vs. 0.952).
Discussion
CESM is a novel breast imaging technique based on dual 
energy acquisition (Daniaux et  al. 2015). A pair of low- 
and high-energy images is acquired. And the two images 
are recombined into one image which looks like a digi-
tal subtraction image. CESM is an advanced application 
Fig. 3 A 62-year-old patient with a 3.5-cm IDC (grade 2) in the right breast. a The low-energy image shows a prominent mass on CC. b The recom-
bined CESM images show an enhanced mass (white arrow) with lobulation and spicule sign on the MLO and CC. c The MRI MIP image of subtraction 
4 min after contrast injection show obvious enhancement of mass (white arrow) with similar appearances to CESM. d Microphotograph indicates 
the diagnosis of IDC lacking myoepithelium (×400, Haematoxylin and eosin)
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Table 1 A detailed overview of pathological diagnosis
Data are percentage (no./total)
Malignant lesions (%) Benign lesions (%)
Invasive ductal carcinoma (n = 36) 46.8 Fibroadenoma (n = 16) 20.8
Ductal carcinoma in situ (n = 5) 6.5 Adenosis (n = 6) 7.8
Intracystic papillary carcinoma (n = 2) 2.6 Granulomatous inflammation (n = 3) 3.9
Invasive cribriform carcinoma (n = 2) 2.6 Intraductal papilloma (n = 2) 2.6
Mucinous carcinoma (n = 2) 2.6 Atypical lobular neoplasia (n = 1) 1.3
Invasive micropapillary carcinoma (n = 1) 1.3 Duct ectasia with cyst (n = 1) 1.3
Fig. 4 A 64-year-old patient with a 2.5-cm lesion in the left breast. a A recombined image on CC shows an enhanced mass (white arrows) with 
several small cystic non-enhanced areas. b A MRI MIP image of subtraction shows inhomogeneous enhancement of mass (white arrows) similar to 
recombined CESM images. c Microphotograph indicates the diagnosis of inflammatory pseudotumor (×400, Haematoxylin and eosin)
Fig. 5 A 47-year-old patient with a 0.4-cm lesion in the left breast. a The low-energy image can’t show the lesion on CC. b The recombined image 
shows a small enhanced lesion (white arrow) on the upper inner quadrant on the CC. c The MRI MIP images of subtraction 4 min after contrast injec-
tion show obvious enhancement of the small mass (white arrow). d Microphotograph indicates the diagnosis of ductal carcinoma in situ. (×400, 
Haematoxylin and eosin)
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of conventional mammography. Prionas et  al. (2010) 
confirmed that the iodinated contrast medium showed 
enhancement of a hypervascular lesion with higher can-
cer detection than conventional mammography. Cheung 
et  al. (2014) analyzed 110 lesions in 89 patients and 
showed that CESM provided additional information with 
consistent improvement of the cancer diagnosis in dense 
breasts compared to conventional mammography alone. 
MRI is considered to be the best modality for breast 
disease diagnosis. When CESM is proposed as a new 
alternative method for screening and diagnosing breast 
cancer, the role of breast MRI is challenged. However, 
the superiority of CESM to MRI is still under debate. Our 
study demonstrated that the diagnosis accuracy of CESM 
(84.4 %, 65/77) was inferior to MRI (89.6 %, 69/77) and 
AUC was 0.96 for MRI and 0.88 for CESM (P <  0.001). 
Nevertheless, the sensitivity of CESM (95.8  %, 46/48) 
appeared superior to that of MRI (93.8  %, 45/48). The 
better correlation with pathology was found for CESM 
than MRI in lesion size assessment.
Currently, breast cancer screening is more popular and 
more available than past in China. The breast tumor can 
be detected in its very early stage and the lesion size is 
smaller than before. In our study, the maximum diame-
ter of the smallest tumor was 0.4 cm. Some small lesions 
were misdiagnosed by using CESM due to lack of char-
acteristics of radiological diagnosis. Therefore, the nega-
tive prediction value (NPV) and the AUC was smaller in 
CESM than breast MRI.
In our study, the specificity of CESM (65.5  %, 19/29) 
was inferior to that of MRI (82.8 %, 24/29). But Jochelson 
(2012) showed that the sensitivity of CESM was higher 
than that of MRI, the specificity had opposite perfor-
mance. Our outcome may be due to the combined appli-
cation of DWI and dynamic contrast enhancement in 
our study, which improved the diagnostic specificity for 
breast cancer. The lack of experiences in CESM diagnosis 
for breast disease may be another reason.
The low-energy image of CESM is similar to conven-
tional mammography. We can detect calcifications and 
the lesions not shown on CESM due to lack of blood sup-
ply. In our study, three fibroadenomas were not found 
Fig. 6 Receiver operating characteristic (ROC) curve for CESM (grey 
line) and MRI (black line). The area under curve (AUC) of ROC in breast 
MRI is larger than that in CESM (z = 2.18, P = 0.03)
Fig. 7 Bland–Altman plots of agreements between a lesion diameter measured using different methods. a The plot shows the agreement between 
CESM and MRI. b The plot shows the agreement between CESM and pathology
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on recombined images whereas clearly shown on low-
energy images due to poor blood supply. According to 
our experiences, low-energy images of CESM could pro-
vide important complementary information when we 
are entangled with final diagnosis by using recombined 
images.
For other diagnostic performances, CESM was better 
in size assessment than MRI. For CESM versus histopa-
thology, the Pearson correlation coefficient was 0.968, 
whereas, for MRI versus histopathology, it was 0.952. The 
mean maximum diameter of lesions was slightly larger 
than that of pathology and the mean maximum diame-
ter of CESM was slightly smaller than that of pathology 
(both P values >0.05). Therefore, CESM can be the better 
modality for determine the lesion extent than MRI.
Of 77 lesions, CESM detected three cancers that were 
misdiagnosed as benign lesions by MRI including one 
intra-cystic papillary carcinoma (2.5 cm) and two DCIS 
(7  mm and 10  mm). The two DCIS showed character-
istics of benign tumors on MRI i.e. regular outline, uni-
form enhancement, typeIof time density curve and ADC 
value of 1.28  ×  10−3  mm2/s. The two lesions showed 
enhancement on combined image and clustered microc-
alcifications on low-energy image by using CESM. DCIS 
is breast malignancy that tends to be misdiagnosed by 
MRI (Teifke et al. 2002; Fallenberg et al. 2014). This may 
be due to a lack of neoangiogenesis in DCIS, resulting in 
less enhancement or more unspecific enhancement in 
MRI. The intra-cystic papillary carcinoma had very few 
enhanced solid components on MRI, but showed irreg-
ular enhanced cyst wall on CESM. Two inflammatory 
granulomas were misdiagnosed by both CESM and MRI 
according to routine diagnostic criteria. We reviewed the 
two cases and speculated that the sign of ring- or honey-
comb-like enhancement may provide clues for the diag-
nosis of inflammatory disease.
There are several limitations in our study. Firstly, the 
contrast agent for CT application is introduced in CESM. 
Therefore, CT contrast agent related risks also apply to 
CESM. Secondly, we didn’t discuss about the radiation 
dose of CESM. Previous studies have shown that the 
radiation dose of CESM is about 20 % higher than con-
ventional digital mammography (Dromain et  al. 2012; 
Yaffe and Mainprize 2011). The dose values of CESM 
meet the recommendations for maximum dose in mam-
mography (Jeukens et al. 2014). We will discuss the risk 
of breast cancer occurrence by using CESM in further 
study on large-sample. Thirdly, the enhanced degree was 
not taken account into the factors of diagnosis. We will 
discuss the correlation between the enhanced degree and 
the pathologic outcomes in further research.
In conclusion, CESM is a new diagnostic method for 
clinics that enables accurate detection and diagnosis 
of breast lesions. CESM should be a good alternative 
method of screening breast cancer in high-risk people. 
However, further studies should be done with a larger 
number of patients to get more convincing results.
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